OrthoPreserve

OrthoPreserve is a Cleveland-based medical device startup founded in 2013, pioneering a novel composite biomaterial meniscus implant. The technology aims to address a critical treatment gap for patients with symptomatic meniscus dysfunction who are not yet candidates for knee replacement, offering a minimally invasive alternative to ineffective conservative treatments or meniscectomy. The company has secured key FDA designations, including Breakthrough Device and TAP program acceptance, and is fundraising to complete pre-clinical testing for an IDE submission targeted for 2027. Its leadership combines engineering innovation with deep clinical orthopedic expertise.

Composite biomaterial engineered to replicate the mechanical properties of natural meniscus tissue, designed for minimally invasive arthroscopic implantation.

The market for meniscus repair devices is established, but the space for meniscus replacement is nascent. Competition includes other early-stage biotech firms and academic groups developing scaffold-based or synthetic meniscus implants, but few have achieved OrthoPreserve's level of FDA regulatory recognition.